Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.
about
Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in GermanyPersonalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.Toward clinical genomics in everyday medicine: perspectives and recommendationsSuicide Gene Therapy for Cancer - Current Strategies.DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Metronomics: towards personalized chemotherapy?Single nucleotide polymorphism and its dynamics for pharmacogenomics.The future of safety science is happening now: The modernization of the benefit-risk paradigm.Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients.The pharmacogenomics of osteosarcoma.Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report.Individualized Integrative Cancer Care in Anthroposophic Medicine: A Qualitative Study of the Concepts and Procedures of Expert Doctors.Genetic polymorphisms in 5-Fluorouracil-related enzymes predict pathologic response after neoadjuvant chemoradiation for rectal cancer.A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patientsPersonalized medicine in oncology: where have we come from and where are we going?The impacts of genetic polymorphisms in genes of base excision repair pathway on the efficacy and acute toxicities of (chemo)radiotherapy in patients with nasopharyngeal carcinoma.Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.Start using a checklist, PRONTO: Recommendation for a standard review process for chemotherapy orders.
P2860
Q28072203-81EE4FD5-534B-4EF8-A09E-80978D641F59Q35107992-4B7A072C-FBA1-4EDC-A722-1F166953EE02Q36825747-C77B31E3-FF99-4C2F-B654-8D523F04CFBCQ37347017-387E72B5-B9F9-4423-BDA1-CCCD8F2AEAC6Q37619866-A4BA7446-95DE-46D7-AEE7-9EA051EC9136Q37685527-12925751-D0EB-42B0-BD84-C8F59EAE428CQ38218923-9FFEDCCB-9601-4460-A7A8-07BC18A8E0FDQ38244756-9645C2E2-BF2C-4E4F-8E46-940C945BFB88Q38673361-2EDE3498-A64E-4F5F-8885-199C085019B6Q38728689-91B3BE45-53CA-4315-B6CC-7FE4F051E677Q38844500-9D248AE1-2F42-4067-BE00-C3304BF26801Q38848413-3A867BC0-BA77-49F7-95AF-0679ABA4941DQ39035865-60420FE9-CB9E-463C-B606-2C5E7DC1FFCFQ39790055-55AAA78E-A639-4040-8CFC-19FE7DA178D7Q40510727-539E3D9E-7FD5-4906-BB46-9274262B4098Q41204464-7E1B1874-9F81-4387-B3AA-9483AD5DE890Q44217256-4290E40C-3C94-4583-825B-C81BCA59C40AQ46140928-7710B686-EE76-4767-9B89-95916E05D8E5Q50567640-502300F0-A0F7-46C2-AD85-1FB336C6F8C2Q53125855-13D03654-9C3E-4259-ABEA-D816759B84CD
P2860
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.
@ast
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.
@en
type
label
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.
@ast
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.
@en
prefLabel
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.
@ast
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.
@en
P2093
P2860
P356
P1433
P1476
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy
@en
P2093
P2860
P304
P356
10.2217/PGS.12.213
P577
2013-02-01T00:00:00Z